Wuhan YZY Biopharma Co., Ltd. Class H

Wuhan YZY Biopharma Co., Ltd. Class H

HHKEX:2496
3.80
HKD
+0.30
(+8.57%)
739.64MMarket Cap
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
0.56
0.34
- -
Basic EPS, GAAP
-0.77
-0.98
-1.04
-0.5
-0.44
- -
Free Cash Flow per Basic Share
-0.52
-0.92
-1.02
-0.53
-0.12
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
0.74
0.81
0.66
0.16
-0.27
-0.3
Tangible Book Value per Share
0.74
0.81
0.66
0.16
-0.27
-0.3
Basic Weighted Avg Shares
193
193
185
194
194
194
Sales/Revenue/Turnover
- -
- -
- -
108
67
- -
Operating Margin (%)
- -
- -
- -
-90.9
-120.52
- -
Depreciation Expense
8
7
7
7
4
- -
Net Income, GAAP
-149
-189
-192
-98
-85
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-90.53
-126.73
- -
Working Capital
69
92
76
35
-69
-105
LT Debt
- -
- -
- -
51
28
- -
Total Equity
143
156
128
31
-53
-59
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-126.31
-135.22
-123.4
- -
- -

Capital Structure

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
102
100
139
LT Borrowings
55
28
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
194
194
194
Market Capitalization
868
1,398
640

Working Capital

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
195
132
131
Cash, Cash Equivalents & STI
166
100
76
Accounts Receivable, Net
5
12
40
Inventories
4
3
2
Total Current Liabilities
212
201
236
Payables & Accruals
- -
- -
- -
ST Debt
102
100
139
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-273.67%
Free Cash Flow
- -
- -
-78.02%
Net Income, GAAP
- -
- -
-13.18%
Sales/Revenue/Turnover
- -
- -
-37.99%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
108
2025
- -
- -
67
2026
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.5
2025
- -
- -
-0.44
2026
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

CEO
Peng Fei Zhou
Full Time Employees
106
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Biolake, C2-1 Wuhan HB China 430075
IPO Date
Sep 25, 2023
Website
yzybio.com
Business
Wuhan YZY Biopharma Co Ltd (2496.HK) is a China-based biotechnology company focused on the discovery, development and commercialization of bispecific antibody (BsAb)-based therapies for cancer, cancer-related complications, age-related ophthalmologic diseases and autoimmune disorders; its core products include M701, a recombinant BsAb targeting EpCAM on cancer cells and CD3 on T cells primarily for malignant ascites (MA) and malignant pleural effusion (MPE), and Y101D, a recombinant anti-PD-L1/anti-TGF-β BsAb for pancreatic cancer and other solid tumors; additional pipelines encompass Y332 (anti-VEGF/anti-TGF-β BsAb for solid tumors), Y225 (Emicizumab biosimilar for hemophilia), Y232 (TL1A×X BsAb for inflammatory bowel disease) and others leveraging proprietary platforms such as Y-BODY, Check-Body and Nano-Ybody. Founded in 2010 and headquartered at No. 666 Gaoxin Avenue, East Lake New Technology Development Zone, Wuhan, Hubei Province, the company operates primarily in China with global rights retention for certain assets and overseas collaboration pursuits; it maintains in-house manufacturing facilities (500L scale) supplemented by CMO/CDMO partnerships and employs 106 staff as of mid-2025. Recent developments include granting exclusive domestic commercialization rights for M701 to CT Tianqing (a Sino Biopharmaceutical subsidiary) in October 2024 for upfront and milestone payments up to RMB1.015 billion plus royalties, completing Phase III enrollment for M701 in MA (312 subjects, BLA planned for 2025), advancing Phase II for M701 in MPE with ESMO 2025 interim data acceptance, finishing Phase Ib/II enrollment for Y101D in pancreatic cancer (CSR due by October 2025), completing Phase I for Y332, transferring Y400 rights to Shenzhen Kangzhe Vision and CMS R&D with ongoing Phase II in nAMD, securing patent grants for M701 formulations and sequences in China and Russia during 2025, and expecting IND approvals for Y225 by end-2025 and Y400 overseas milestones.